Form 4: Revelation Biosciences Director Boosts Stock Holdings

Revelation Biosciences Director Jennifer Carver acquired 41,981 shares of common stock through a restricted stock unit grant.

Summary

• Jennifer Carver, a Director at Revelation Biosciences, Inc. (REVB), acquired 41,981 shares of common stock.
• The transaction occurred on January 8, 2026, at a price of $0.9 per share.
• These shares are Restricted Stock Units (RSUs) granted under the company's 2021 Equity Incentive Plan.
• The RSUs will vest quarterly over one year from the date of grant.
• Following this transaction, Jennifer Carver directly beneficially owns 57,669 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, particularly through an RSU grant, is generally viewed positively as it aligns management's interests with shareholders and indicates confidence in the company's future, even if it's part of a compensation package.

Positives

• Director Jennifer Carver increased her direct beneficial ownership in Revelation Biosciences, Inc. by 41,981 shares.
• The acquisition of Restricted Stock Units (RSUs) aligns the director's interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The grant is part of the 2021 Equity Incentive Plan, indicating a structured approach to executive compensation and retention.

Negatives

• No specific negative information is disclosed in this Form 4 filing, which primarily reports an insider transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The Restricted Stock Units granted to Director Jennifer Carver are scheduled to vest quarterly over one year from the grant date, indicating a future commitment and retention mechanism for key management.

Management Comments

• Not applicable, as Form 4 filings do not typically include management commentary beyond the transaction details.

Industry Context

Insider transactions, such as the grant of Restricted Stock Units, are a common practice in the biotechnology industry to incentivize and retain key directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Not applicable for a Form 4 filing, which reports a specific insider transaction rather than operational or financial results.

Corporate Governance

Related Party Transactions

• The transaction involves a director acquiring shares from the issuer, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to direct ownership of company stock.
• Employees: The use of an equity incentive plan may signal a commitment to performance-based compensation, potentially impacting employee morale and retention.

Next Steps

• The Restricted Stock Units will vest quarterly over one year from the grant date of January 8, 2026.

Key Dates

Keywords

Revelation Biosciences, REVB, insider transaction, Form 4, Jennifer Carver, Director, common stock, RSU, Restricted Stock Unit, equity incentive plan, beneficial ownership